Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
EPM
EPM Overview
EPM develops prescription medicine derived from synthetic cannabinoid acids to address unmet patient needs.
The company has created a pipeline that includes the discovery of 14 protected synthetic molecules, including eight novel structures and production process intellectual property.
Currently, EPM's focus is on two main therapeutic conditions: metabolic disorders (Prader-Willi syndrome) and inflammatory skin disease (psoriasis).